Rasonque Doubles Survival, Then Posts a $39,800 Price

The FDA last week approved Rasonque, a daily pill that nearly doubled survival in advanced pancreatic cancer, then posted a $39,800 monthly list price. The generic name is daraxonrasib, made by Revolution Medicines of Redwood City, California. It is the first approved medicine built to block several forms of RAS, the growth switch that drives most pancreatic tumors.

Acting Commissioner Kyle Diamantas said the agency’s “fundamental duty” is to get meaningful treatments to patients as quickly as possible. The chemistry problem that stalled this field for decades is no longer the wait. The next wait is coverage, copays, and a survival clock that is better, not long.

Survival Time Moved From 6.7 to 13.2 Months

Approval rests on RASolute 302, a global open-label phase 3 trial in 500 adults with metastatic pancreatic adenocarcinoma whose disease had already progressed after one line of systemic therapy. Investigators assigned 248 people to daraxonrasib and 252 to a doctor’s choice of standard chemotherapy. About 91.8% of tumors carried a RAS G12 mutation, the most common RAS change in this disease.

The FDA’s review found a median overall survival of 13.2 months with the pill versus 6.7 months with chemotherapy. The hazard ratio was 0.40, a 60% cut in the risk of death. Median time without progression was 7.2 months versus 3.6 months. Tumors shrank in 30% of patients on the pill and 11% on chemo.

RASOLUTE 302, OVERALL POPULATION

Patients also kept function longer. In the company’s readout of the same trial, time until global quality of life worsened was 5.7 months on Rasonque and 2.6 months on chemo. Time until pain got worse was 9.2 months versus 3.8 months. The dose that moved into phase 3, and onto the label, is 300 mg by mouth once a day until the cancer grows or the side effects cannot be managed.

This approval gives physicians the confidence that directly inhibiting RAS can make a striking difference for patients and provides a critically needed new approach to treating patients with metastatic pancreatic cancer.

Brian M. Wolpin, M.D., M.P.H., director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, and principal investigator of RASolute 302

Dr. Andrew Coveler of Fred Hutch Cancer Center called it one of the most anticipated approvals he can think of, and he was plain about the limit: the medicine is not a cure. Common effects include rash, diarrhea, mouth sores, nausea, fatigue, vomiting, belly pain, swelling, loss of appetite, and bleeding. The label also warns about skin and soft-tissue injury, holes in the gut, and interstitial lung disease.

9800 monthly price” style=”width:100%;max-width:800px;height:auto;border-radius:8px;display:block;margin:0 auto;” />

9800 monthly price” style=”width:100%;max-width:800px;height:auto;border-radius:8px;display:block;margin:0 auto;” />

9800 monthly price” style=”width:100%;max-width:800px;height:auto;border-radius:8px;display:block;margin:0 auto;” />

9800 monthly price” style=”width:100%;max-width:800px;height:auto;border-radius:8px;display:block;margin:0 auto;” />

What a Month of Rasonque Costs

Revolution Medicines set a wholesale acquisition cost of $39,800 for a 30-day supply at the 300 mg daily dose. Taken for a full year, that list price is $477,600. Company executives said the figure matches the survival gain in RASolute 302. Eligible people with commercial insurance may pay as little as $0 through the new (ON)Path patient support program, which also helps with prior authorization and start-up supply if an insurer stalls.

Most people with this cancer are older, and the company expects Medicare Part D to be the main payer. Manufacturer copay cards of this kind usually cannot be used with Medicare or Medicaid. That split is the quiet hitch inside a launch that otherwise looks frictionless: the $0 path is built for commercial plans, while the typical patient is on a government plan with its own deductible and out-of-pocket rules.

THE STICKER AND THE FINE PRINT

• List price: $39,800 for a 30-day supply before discounts and rebates.
• Full-year list: $477,600 if a patient stays on the 300 mg daily dose for 12 months.
• Commercial copay: as little as $0 a month for people who qualify for (ON)Path.
• Medicare: oral oncology usually runs through Part D, where the copay card generally does not apply.

A longer median life also means more months of invoices. People who already received the drug at no charge under expanded access now need a covered prescription. Revolution Medicines said uninsured and underinsured patients who meet medical and financial tests can still get the pills free, and it is offering a short free supply while coverage is sorted. The remaining risk sits with high-deductible commercial plans, especially in January when deductibles reset.

The speed of the review is part of that scramble. The application was accepted on July 22 and approved 35 days later, on August 26, about 6.5 months ahead of the user-fee deadline. It moved under the Commissioner’s National Priority Voucher pilot, a 2025 program built to cut review time to 1 to 2 months with a tumor-board-style meeting instead of the usual 10 to 12 months. Breakthrough Therapy, Orphan Drug, and Priority Review tags sat on the file as well.

THE PATH TO THE LABEL

1. October 16, 2024: RASolute 302 begins enrolling previously treated metastatic pancreatic adenocarcinoma.
2. October 2025: The FDA issues a national priority voucher for daraxonrasib, then still coded RMC-6236.
3. May 1, 2026: The agency clears an expanded-access protocol two days after the company asked, and the pills go out free of charge to eligible patients.
4. July 22, 2026: The new drug application is accepted for review.
5. August 26, 2026: Rasonque is approved and the company says tablets are available by prescription in the United States.

Former Sen. Ben Sasse of Nebraska described on 60 Minutes how he had less pain while taking the then-investigational drug, and that broadcast helped push demand for early access. Public attention can open a protocol. It cannot write a Part D formulary.

Chemists Called RAS Undruggable for Decades

RAS is a protein that tells a cell when to grow. When the gene that makes it is mutated, the switch sticks in the on position. That is the main engine of pancreatic adenocarcinoma, and it is a driver in large shares of lung and colorectal cancer as well. For years the protein’s shape left no obvious pocket for a drug to grip, so textbooks and clinic notes treated it as a finding with no medicine attached.

Daraxonrasib is an oral RAS(ON) multi-selective tri-complex inhibitor. In plain terms, it acts as a molecular glue. It latches onto RAS when the protein is in its active, GTP-bound state, covering both many mutant forms and the normal protein, and it blocks the downstream growth signal. The FDA called it a first-in-class RAS inhibitor for the most common form of pancreatic cancer. Revolution Medicines calls it the first broad RAS-targeted medicine in this disease, a phrase that matters because earlier RAS work in other tumors often chased a single narrow variant.

No companion diagnostic is required. The approved use covers adults with metastatic pancreatic adenocarcinoma with or without an identified RAS mutation. That choice matches the trial, which enrolled a wide mix of RAS genotypes and still showed the survival gain in the full 500-person group. It also means a patient does not have to wait on a specialized test before a prescription can be written.

Angelo de Claro, M.D., director of the FDA’s Oncology Center of Excellence, said the drug showed results the agency called unprecedented in a setting of high unmet need. At the 2026 American Society of Clinical Oncology meeting, where the phase 3 data were presented as the New England Journal of Medicine published them, the American Cancer Society later noted that thousands of doctors stood during the talk. Standing ovations do not fill a pill box. They do explain why the expanded-access line formed before the label existed.

The Approved Use Covers More Than the Study

RASolute 302 tested people who had already received one prior line. The FDA indication is wider than that sample. It covers adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. The second clause is the opening. A patient who cannot take combination chemo can, on the text of the label, start the pill without first failing a multi-drug infusion.

Anirban Maitra, a pancreatic cancer researcher and pathologist, wrote that the approval is “REALLY broad,” that the “OR” “potentially opens the door for a soft 1st line extension,” and that there is “no requirement to document KRAS status.” Insurers may still try to cabin the drug to the exact trial population because of the price. The legal text doctors will cite is the broader sentence the FDA printed.

WHO THE LABEL INCLUDES

• The disease: adult metastatic pancreatic adenocarcinoma, the form that starts in duct-lining cells and makes up about 90% to 95% of U.S. pancreatic cancers.

Prior treatment: at least one earlier systemic therapy, or a patient who is not a candidate for multiagent chemo.

• Mutation testing: not required; the trial’s overall group, with and without an identified RAS change, supported the claim.
• How it is taken: 300 mg orally once daily, at home, until progression or unacceptable toxicity.

Anna Berkenblit, M.D., chief scientific and medical officer at the Pancreatic Cancer Action Network, said an oral pill can be less burdensome than standard intravenous chemo and that the approval is the most significant advance she has seen against this disease. Mark A. Goldsmith, M.D., Ph.D., chief executive of Revolution Medicines, said patients now have a targeted medicine aimed at the main cause of pancreatic cancer, “one of the most intractable disease targets since its discovery decades ago.”

Dr. Pashtoon Kasi of City of Hope Orange County said the result has opened doors for other companies, with more trials likely in other tumor types. That is the second bill the $39,800 price is trying to anticipate: a franchise, not a single last-line niche.

This Cancer Still Has a 13% Five-Year Survival

The American Cancer Society’s 2026 estimates say about 67,530 people will be diagnosed in the United States (35,190 men and 32,340 women) and about 52,740 will die (27,230 men and 25,510 women). Pancreatic cancer is about 3% of U.S. cancers and about 8% of cancer deaths. Lifetime risk is about 1 in 56 for men and 1 in 60 for women.

The FDA notes that despite being roughly 3.2% of diagnoses, pancreatic adenocarcinoma accounts for a high share of deaths because it is found late, runs fast, and had few good drugs. Revolution Medicines says about 80% of patients are diagnosed after the disease has already spread. In that distant-stage group, five-year relative survival is 3%.

SEER FIVE-YEAR RELATIVE SURVIVAL

Those figures, from the American Cancer Society using people diagnosed from 2015 to 2021, predate Rasonque. The all-stage five-year relative survival rate of 13% is the same number that sat in last year’s report. It is better than the 3% recorded for 1975 to 1977, and better than the 4% of the mid-1990s. It is still the clock this pill is being asked to move, one last-line median at a time.

A gain from 6.7 months to 13.2 months is a near doubling of a short interval. Half the people on the new drug still died by a little over a year. That is why Coveler’s caution belongs next to Goldsmith’s claim of a new standard of care, not underneath it.

Other RAS Cancers Are Already in Late Trials

Rasonque is now a commercial tablet in one setting. The same molecule is still investigational everywhere else. The company is running a global phase 3 program in metastatic RAS-mutant non-small cell lung cancer, and the FDA has already given Breakthrough Therapy designation for previously treated locally advanced or metastatic NSCLC with KRAS mutations other than G12C, after platinum chemo and PD-1 or PD-L1 antibody therapy. That lung study, RASolve 301, compares the pill with docetaxel.

A separate phase 3 trial, RASolute 304, is testing adjuvant daraxonrasib against observation in people whose pancreatic tumors were removed and who have finished peri-operative chemo. It started on December 15, 2025. If that study works, the $39,800 conversation moves from last-line metastatic care into earlier disease, where patients may take the drug longer.

Outside the United States the pill is not approved. The FDA reviewed the file under Project Orbis with Health Canada, while the European Medicines Agency and Japan’s PMDA sat as observers. EMA has started a phased review and has given the compound orphan status for pancreatic cancer plus a high-priority slot in its Cancer Medicines Pathfinder project.

Pharmacists who used to translate a RAS result as “nothing we can do” now have a product to dispense, a prior authorization to fight, and a rash to counsel. The protein did not get easier. The glue did.

Frequently Asked Questions

Does Rasonque Require a Genetic Test Before It Is Prescribed?

No. The FDA did not tie the pancreatic indication to a companion diagnostic, and Revolution Medicines says the approval covers metastatic pancreatic adenocarcinoma with or without an identified tumor RAS mutation. Doctors may still order sequencing for other reasons, including clinical-trial matching, but the label does not make a RAS result a gate for the prescription.

What Serious Risks Sit on the Label Besides Rash and Diarrhea?

Beyond the common effects, prescribing information warns about dermatologic and soft-tissue toxicity, stomatitis and other mouth disorders, diarrhea, gastrointestinal perforation, interstitial lung disease or pneumonitis, and embryo-fetal toxicity. Those last three are the ones that change monitoring and pregnancy counseling, not just comfort care.

Is the Drug Being Tested After Pancreatic Surgery?

Yes. RASolute 304 (NCT07252232) is a phase 3 study of adjuvant daraxonrasib versus standard observation in patients with resected pancreatic ductal adenocarcinoma who have already completed neoadjuvant or adjuvant chemotherapy. The trial’s actual start date is December 15, 2025, with primary completion estimated in May 2029, so any move into post-surgery care is years from a result.

Which Other Countries Are Reviewing Daraxonrasib?

The U.S. review ran under Project Orbis, with Health Canada as a collaborator and the EMA and Japan’s PMDA as official observers. EMA has begun a phased review that lets assessors read data as they arrive, before a full marketing application, and has granted orphan medicinal product designation for pancreatic cancer. No non-U.S. approval has been issued.

How Did the National Priority Voucher Change the Clock?

Sponsors redeeming a Commissioner’s National Priority Voucher aim for a decision in 1 to 2 months after the complete application, instead of 10 to 12. They must file chemistry, manufacturing, and controls plus draft labeling at least 60 days before the final application, stay available for rapid questions, and sit through a multidisciplinary, tumor-board-style review. The FDA can still stretch the window if the package is thin or the trial is messy.

Onco360 is among the specialty pharmacies named as a national partner for launch. Tablets are listed as available now. The remaining work is ordinary and hard: a prior authorization, a Part D exception, a rash that needs a steroid cream, and a follow-up scan at a time point that used to arrive after the patient was already gone.

Disclaimer: This article is news reporting and analysis of an FDA approval and published trial results, and it is for information only. It is not medical advice, a treatment recommendation, or a substitute for care from an oncology team, and it is not advice about insurance, copays, or whether any person should start, stop, or switch a cancer drug. Readers should talk with a board-certified oncologist and, for coverage questions, a pharmacist or plan benefits specialist who can review the actual label, the person’s diagnosis, and their insurance. Survival figures, prices, copay rules, and trial statuses reflect the FDA, company, and American Cancer Society materials available as of September 2, 2026, and all of those items can change.